The majority of risk evaluation and mitigation strategies (REMS) come with fairly straightforward elements—but what about those that require elements to assure safe use (ETASUs)? How does the complexity of a REMS program impact access to a therapy and healthcare providers’ willingness to prescribe it?
Join us on Tuesday, May 25 at 2PM (Eastern) for the second presentation in our five-part webcast series, “Ensuring Patient Access to Products in the Evolving Healthcare Market.” In part two, Terri Madison, Vice President – Epidemiology and Risk Management for Xcenda, and Derek Cothran, Senior Director for Lash Group, will discuss how a successful REMS program should be designed to minimize burden for healthcare providers and other stakeholders who must follow it. Madison and Cothran will also explore how an effective REMS program can provide timely metrics, real-world outcomes evidence and support key product objectives, like therapy adherence and patient access.
Other topics for discussion will include:
PRESENTERS
Terri Madison, PhD, MPH
Vice President - Epidemiology and Risk Management
Xcenda
Derek Cothran, MHA
Senior Director
Lash Group